In mouse tumor models, LeMercier et al. presented that using monoclonal antibodies against VISTA resulted in reduced an inhibitory function of VISTA and the number of tumor-associated FoxP3+ CD4+ Tregs. The gene discussed is CD4; the disease is neoplasm.